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SHORT TITLE 
HIV antibodies and reservoir size characterization in children 
 
  
SYNOPSIS 
 
Background 
The absence of detectable viremia after treatment cessation in some vertically HIV-infected (VHIV) children 
suggests that early initiation of highly active combination of antiretroviral therapy (HAART) could lead to 
functional cure.  
Objectives 
We described the factors associated with HIV antibody levels and the viral reservoir size in HAART-treated VHIV 
children.  
Patients and methods 
This study included 97 VHIV children with virological suppression, in Bamako, Mali. The anti-gp41 antibody 
activities and HIV serostatus were assessed. The viral reservoir size was measured by quantifying total cell 
associated HIV DNA. 
Results 
Among the children studied, the median total HIV DNA level was 445 copies/106 cells (IQR = 187 - 914), the 
median anti-gp41 antibody activity was 0.29 OD (IQR = 0.18 - 0.75). Low activity of anti-gp41 antibodies was 
associated with a younger age of HAART initiation (p = 0.01). Overall, eight HIV-1 seroreversions were 
identified. 
Conclusion 
This study identified potential candidates with low viral reservoir and low antibody levels or activities for future 
trials aiming to reduce HIV-1 reservoir in order to limit HAART duration.  
MANUSCRIPT 
 
INTRODUCTION 
 Pediatric HIV infection remains a major public health issue despite large implementation of prevention 
of mother-to-child transmission programmes. 1 It requires early and lifelong HAART to control the viral 
replication with a risk of accumulating toxicity and viral drug resistance. International guidelines are now 
recommending initiation of HAART in all vertically HIV-1-infected (VHIV) children regardless of clinical and 
immunological conditions 2 as early treatment reduces mortality and improves immune recovery. 3 
 Proviral DNA HIV-1 reservoirs are established early during infection and represent a barrier to 
functional cure. 4 A low HIV viral reservoir is associated with a lower risk of disease progression. Despite 
prolonged HAART, HIV-1 persists as transcriptionally inactive proviruses in long half-life memory resting CD4 T 
cells.5 The lowest reservoir has been described in elite controllers (EC) in whom HIV-1 replication is controlled 
without treatment. 6 However, in post-treatment controllers (PTC), HIV-1 remission and low reservoir are 
observed after HAART interruption mainly when treatment was initiated during primary HIV infection (PHI). 7 
The relation between the size of the viral reservoir, and the precocity and duration of HAART has been 
previously described in children. 8–10 However, more studies are required to identify simple predictors of the 
reservoir size in VHIV children, in real world conditions within high HIV prevalence settings, especially in VHIV 
children. 
 The absence of detectable viremia 12 years after treatment cessation in one VHIV child has suggested 
that early HAART initiation could lead to functional cure. 11 HIV infected people first develop anti-gp41 
antibodies and only several weeks later, anti-gp120 antibodies. 12 The Berlin patient, who was cured of HIV 
following a stem cell transplant, dysplayed a complete loss of anti-p24 antibodies and a low but still detectable 
response to gp41. 13 Only few EC subpopulations show this HIV antibody profile. Thus, monitoring the response 
to p24 and gp41 may be useful in HIV cure studies. 
 Several HIV-1 seroreversions have been observed in VHIV children who initiated HAART within the first 
months of life. 14,15 By blocking viral replication, the early virostatic treatment might prevent the development 
of the HIV-1 specific antibody response, either quantitatively (antibody level) or qualitatively (antibody 
activity), thus leading to HIV seroreversion or substantially lower anti-HIV antibody levels. One analysis 
demonstrated that age of HAART initiation and plasma viral load were strong predictors of serostatus, and both 
were independently associated. 16 Kuhn et al showed that the absence of HIV antibody response indicated a 
smaller HIV-1 viral reservoir, and HAART initiated at 3 months of age was the upper limit  to see the benefits of 
early HAART. 17 Only one study has desmontrated the utility of HIV serostatus as a surrogate marker of the 
reservoir size. 8 
Here we describe the factors associated with HIV antibody activity or level and the viral reservoir size 
in HAART-treated VHIV children with heterogeneity of age, time of therapy, and duration of virological 
suppression.  
METHODS  
This cross-sectional study conducted within a prospective cohort included HAART-treated VHIV 
children followed at Gabriel Touré Hospital (Bamako, Mali) with sustained virological suppression (HIV-1 RNA 
plasma ≤ 50 copies/mL). All participants were known virologically suppressed at their previous visit (six months) 
and confirmed during the study. Participants older than 20 years old, those with HIV-2 infection, treated for 
less than three months, or without any data recorded were excluded from the study. After obtaining the 
parent’s written or oral informed consent from all participants, five millilitres of extra blood samples were 
collected in EDTA tubes during the routine follow up visit. Assent was obtained from child participants 
according to local institutional review board guidelines. The study was approved by the National AIDS program 
at the Ministry Of Health in Mali (CSLS/MS) in collaboration with the Malian Institutional Ethics Committee at 
the Faculty of Medicine, Pharmacy and Odontostomatolgy of health and life sciences in Bamako under the 
reference number N°10-05-FMPOS. 
 In order to evaluate the size of the HIV-1 viral reservoir, total DNA was extracted from PBMC’s derived 
from whole blood using an automated technique (MagNA Pure, Roche, Manheim, Germany). The cell-
associated HIV-1 DNA level was quantified using a real-time PCR method which amplifying a region in the LTR 
gene, as previously described. 18 Proviral burden was expressed as HIV DNA copies per 1 million cells 
(quantification limit: 10 copies/PCR, i.e. 66 copies/106 cells considered as undetectable). 
 Dried serum spots (DSS) were used to evaluate the HIV-specific antibody response. The level of 
antibodies targeting the gp41 immunodominant epitope (IDE) was measured following a previously described 
protocol. 19 An equimolar mixture of two 30 amino-acids oligopeptides was used, representing the IDE 
consensus sequences of HIV-1 group M and subtype D, respectively. A low mixture concentration allowed the 
binding of late antibodies that had acquired sufficient avidity and then semi-quantitative detection by 
spectrophotometry. The result was expressed as an optical density (OD). The activity of anti-gp41 antibodies 
was systematically tested in quadruplicate. 
 The 4th generation ARCHITECT HIV Ag/Ab Combo assay (Abbott Laboratories, Wiesbaden, Germany) 
was performed as previously described to quantify the humoral response in DSS. The result was defined as 
relative light units, then compared to a cut-off signal. Samples with signal-to-cut-off (S/CO) values ≥ 1.00 were 
considered reactive and those < 1.00 non-reactive. 
 We used univariate association between HIV DNA level, anti-gp41 antibody activities or HIV-antibody 
levels and variables defining current and past HIV disease (age, sex, WHO stage at study, HAART type at study, 
CD4 cell count at study, HAART duration, maternal prophylaxis type, age at HAART initiation), with the 
Spearman rank correlation coefficient for continuous variables and the Fisher’s exact test for categorical 
variables. 
RESULTS 
 From August 2013 to April 2014, 97 VHIV children with virological suppression were enrolled. Their 
median age was 9.8 years old at time of inclusion (IQR = 7 – 13.1), they started HAART at a median age of 3.3 
years (IQR = 1.9 - 7), and were receiving HAART for a median 5.4 years (IQR = 3.5 - 7). Table 1 summarizes the 
demographic, immunologic and virologic characteristics of the children. 
 The median anti-gp41 antibodies activity was 0.29 OD (IQR = 0.18 - 0.75). A low activity of anti-gp41 
antibodies was associated with both a younger age at treatment initiation (p = 0.01; Figure 1) and with a lower 
level of anti-HIV antibodies (p = 0.0015; Figure 1). Overall, eight seroreversions were identified (negative ELISA 
Architect) in which 2 children had an HIV DNA under the threshold (1 detectable and 1 undetectable) and a low 
anti-gp41 antibodies activity. All the seroreverted children started HAART before two years of age, at a median 
age of 1.1 years, and were on HAART for the past 7.3 years in median. 
 The median level of total HIV DNA was 445 copies/106 cells (IQR = 187 – 914). No correlation was 
found between anti-gp41 antibodies activity or age at treatment initiation and HIV DNA (p = 0.27; Figure 1). 
The 9 children with an HIV DNA level under the threshold tended to have a lower anti-gp41 antibodies activity 
compared to children with an HIV DNA > 66 copies//106 cells (p = 0.11). 
DISCUSSION 
 This study indicates that a significant proportion of virologically suppressed VHIV children who 
initiated HAART before the age of two years stopped to produce and/or progressively lost the HIV antibodies. 
This is consistent with the idea that early HAART halts the antigenic stimulation which is necessary to sustain an 
HIV-specific antibody response. 8-10,20 In addition, some of these children with seroreversion had a very low HIV 
reservoir, at least identified in the peripheral blood, and could therefore represent an ideal population for 
studies investigating novel immunotherapeutic strategies aiming to achieve HAART-free remission.  
 Although current HAART can effectively control HIV replication to clinically undetectable levels for 
years, existing strategies do not eradicate HIV-1 reservoirs in VHIV children. 11 One of the limitation of our 
study was that our cohort did not include children who started HAART before five months of life, and therefore 
we were not able to identify more seroreversions. Nonetheless, we found 50% of seroreversion in VHIV 
children who initiated treatment before two or one years old (8/16 and 4/8 respectively), consistently with 
other studies in occidental settings that showed 50% to 94% of seroreversion when treatment was initiated 
before 3 months of life. 14,15,20 
 Children can acquire HIV-1 in utero, during delivery or breastfeeding. 1 In our study, the time of HIV 
transmission was not known. But, we assumed that seroreversion probably occured in children who had 
treatment initiation soon after the HIV infection acquisition. Indeed, when using one of the most sensitive 
assays available, we were able to find several seroreversions. In addition, we found an association between a 
low anti-gp41 antibodies activity and a younger age at treatment initiation. 
 Early effective control of HIV replication has been associated with incomplete development of HIV-
specific immune responses in children. 14,15,20 It would be of interest to study the initial development of anti-HIV 
antibodies (like activity and quantification of anti-gp41 antibodies ) in early treated infants to determine 
whether the primary responses is affected or the influence occurs later on, leading to a decrease of responses 
over time. The decrease of antibody production and/or their avidity against some epitopes should reflect the 
absence of circulating antigenic viral particles, showing the absence of residual viral replication.   
 In conclusion, the results of this study show that HIV-1 seroreversion and low anti-gp41 activity in 
VHIV children with early HAART initiation happened and should be considered as a proof-of-concept study to 
evaluate strategies targeting HAART-free remission (i.e long-term undetectable viremia for an undefined 
period, in the absence of HAART). 21 This study identified potential candidates with low viral reservoir and low 
antibody levels or activity. Defining the immunologic and virologic end-points after HAART in VHIV children and 
identifying factors and biomarkers associated with limited proviral reservoir size are essential to define 
therapeutic strategies, in order to achieve HIV remission or cure in this population. 
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Table 1 : Descriptive characteristics of HAART-treated VHIV children with virologic suppression 
Abbreviations : cART, combination of antiretroviral therapy; HAART, highly active combination of antiretroviral 
therapy; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside 
reverse transcriptase inhibitor; OD, optical density; PI, protease inhibitor; S/CO, signal-to-cutoff; WHO, Word 
Health Organization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Characteristics n (%) Median (IQR) Global range 
Age (years) - 9.8 (7 - 13.1) 2.8 - 19 
Sex :    
   Female 38 (39) - - 
   Male 59 (61) - - 
cART maternal prophylaxis type :    
   2 NRTI + 1 NNRTI 60 (62) - - 
   2 NRTI + 1 PI 37 (38) - - 
Age at HAART initiation (years) - 3.3 (1.9 - 7) 0.41 - 16 
Duration of HAART (years) - 5.4 (3.5 - 7) 0.33 - 12.1 
WHO stage at HAART initiation:    
   1 or 2 36 (39) - - 
   3 or 4 52 (61) - - 
Missing data : 9    
HAART type at study :    
   2 NRTI + 1 NNRTI 61 (63) - - 
   2 NRTI + 1 PI 36 (37) - - 
CD4 cell count at study (cells/mm3) - 820 (605 - 1120) 46 - 2000 
   Missing data : 1    
HIV DNA level at study (copies/106cells) - 445 (87- 902) 0 - 7378 
   < 66 copies/106cells (i.e undetectable) 12 (13) - - 
Missing data : 2    
Anti-gp41 antibodies activity at study (OD) - 0.29 (0.18 - 0.75) 0.09 - 2.23 
   Missing data : 9    
Anti-HIV antibodies level at study (S/CO) - 14.1 (4.1 - 39.3) 0.31 - 520.6 
   < 1.0 S/CO (i.e seroconversion) 8 (9) - - 
Missing data : 10    
  
Figure 1: Distribution of anti-gp41 antibodies activity by age at HAART initiation (A) and by anti-HIV antibodies 
level (B) using Spearman correlation. Distribution of HIV DNA level by age at HAART initiation (C) and by anti-
gp41 antibodies activity (D) using Spearman correlation. 
 
 
 
Abbreviations: HAART, highly active combination of antiretroviral therapy; OD, optical density; S/CO, signal-to-
cutoff 
Anti-gp41 antibodies activity measured by manual immuno-enzymatic assay 
Anti-HIV antibodies level measured by a 4th generation ARCHITECT HIV Ag/Ab Combo assay 
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